Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
Public ClinicalTrials.gov record NCT04571645. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dociparstat Sodium in Combination With Standard Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 3 study to evaluate the efficacy and safety of dociparstat sodium in adults with newly diagnosed untreated acute myeloid leukemia (AML) with adverse or intermediate genetic risk.
Study identification
- NCT ID
- NCT04571645
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 9 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2021 (Actual)
- Primary completion
- May 16, 2022 (Actual)
- Completion
- May 16, 2022 (Actual)
- Last update posted
- Apr 15, 2024
2021 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Irvine Medical Center | Orange | California | 92868 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Norton Cancer Institute, St. Matthews Campus | Louisville | Kentucky | 40207 | — |
| Tulane University School of Medicine | New Orleans | Louisiana | 70112 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Allina Health System / Virginia Piper Cancer Institute | Minneapolis | Minnesota | 55407 | — |
| New York Medical College | Hawthorne | New York | 10595 | — |
| Mount Sanai School of Medicine | New York | New York | 10029 | — |
| East Carolina University Vidant Medical Center | Greenville | North Carolina | 27834 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Spartanburg Medical Gibbs Cancer Center | Spartanburg | South Carolina | 29303 | — |
| Baylor | Dallas | Texas | 75246 | — |
| University of Utah / Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04571645, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 15, 2024 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04571645 live on ClinicalTrials.gov.